Optimal regimens of sulfamethoxazole-trimethoprim for chemoprophylaxis of Pneumocystis pneumonia in patients with systemic rheumatic diseases: results from a non-blinded, randomized controlled trial
详细信息 查看全文
- 作者：Masako Utsunomiya ; Hiroaki Dobashi ; Toshio Odani…
- 关键词：Pneumocystis pneumonia ; Sulfamethoxazole ; trimethoprim ; Prophylaxis ; Efficacy ; Safety ; Drug discontinuation rate ; Rheumatic disease ; Randomized controlled trial
- 刊名：Arthritis Research & Therapy
- 出版年：2017
- 出版时间：December 2017
- 年：2017
- 卷：19
- 期：1
- 全文大小：947KB
- 刊物主题：Rheumatology; Orthopedics;
- 出版者：BioMed Central
- ISSN：1478-6362
- 卷排序：19
文摘
BackgroundSulfamethoxazole-trimethoprim (SMX/TMP) is a standard drug for the prophylaxis of Pneumocystis pneumonia (PJP) in immunosuppressed patients with systemic rheumatic diseases, but is sometimes discontinued due to adverse events (AEs). The objective of this non-blinded, randomized, 52-week non-inferiority trial was to quest an effective chemoprophylaxis regimen for PJP with a low drug discontinuation rate. Results at week 24 were reported.